It appears he was the fourth highest paid executive and remains a potentially sizeable shareholder. His bio had seemed pretty good. (Below)

Anyone know how much of a loss this might be to the conpany. ? 

Mr. Lebioda has over 30 years of experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access.

Mr. Lebioda’s past contributions helped build leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro. He is responsible for leading the Company's efforts in product portfolio strategy, pharmacoeconomics, reimbursement, licensing and commercial development.

Ken is an accomplished musician and enjoys travelling with his family.